Title:
BIONANOCAPSULE HAVING ANTIBODY AGAINST SURFACE PROTEIN OF DENDRITIC CELL
Document Type and Number:
WIPO Patent Application WO/2013/147232
Kind Code:
A1
Abstract:
The purpose of the present invention is to provide a vaccine which can meet a market need satisfactorily. The purpose can be achieved using a bionanocapsule which has an antibody against a surface protein of a dendritic cell and also has a virus-like particle containing a virus surface antigen protein.
Inventors:
KURODA SHUN ICHI (JP)
MATSUO HIDENORI (JP)
YOSHIMOTO NOBUO (JP)
IIJIMA MASUMI (JP)
ARAKAWA TAKESHI (JP)
MATSUO HIDENORI (JP)
YOSHIMOTO NOBUO (JP)
IIJIMA MASUMI (JP)
ARAKAWA TAKESHI (JP)
Application Number:
PCT/JP2013/059691
Publication Date:
October 03, 2013
Filing Date:
March 29, 2013
Export Citation:
Assignee:
UNIV NAGOYA NAT UNIV CORP (JP)
UNIV RYUKYUS (JP)
UNIV RYUKYUS (JP)
International Classes:
A61K39/12; A61K9/127; A61K31/7088; A61K39/00; A61K39/395; A61K48/00; A61P31/14; A61P31/16; A61P31/18; A61P31/20; A61P31/22; C07K14/005; C07K16/28; C12N5/0784; C12N15/09
Domestic Patent References:
| WO2003082330A1 | 2003-10-09 |
Other References:
WEI,H. ET AL.: "Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice", CLIN CANCER RES, vol. 15, no. 14, 2009, pages 4612 - 21, XP055089726, DOI: doi:10.1158/1078-0432.CCR-08-3321
MATSUO,H. ET AL.: "Engineered hepatitis B virus surface antigen L protein particles for in vivo active targeting of splenic dendritic cells", INT J NANOMEDICINE, vol. 7, 2012, pages 3341 - 50
MATSUO,H. ET AL.: "Engineered hepatitis B virus surface antigen L protein particles for in vivo active targeting of splenic dendritic cells", INT J NANOMEDICINE, vol. 7, 2012, pages 3341 - 50
Attorney, Agent or Firm:
SAEGUSA & PARTNERS (JP)
Patent business corporation 3 Edakuni [Hajime] patent firm (JP)
Patent business corporation 3 Edakuni [Hajime] patent firm (JP)
Download PDF: